This is very interesting. I think it points to the therapeutic targets of medications 10 to 12 years down the pipeline, unless it merges with current probiotic research - then it might only be 6-8 years down the pipeline.
The key phrase is "hopefully over the long-term will help us discover aspects that we can target with new therapies"
They find that a gene that make a protein Bcl-3, is over-expressed in IBD. They find that this protein blocks an immune system signal called p50, which results in too few TReg cells to down-regulate inflammation.
They want to "search for new active agents that will prevent the interaction between Bcl-3 and p50". I assume they could also look for things that would lower expression of Bcl-3 in the GI track. (I assume it is needed elsewhere in the body.)
Whatever they find will need trials to determine it is safe, and that there are no unwanted side effects elsewhere in the body.
There is also a lot of research showing the importance of the gut microbes in IBD, so it would encourage me if there was some link between Bcl-3 and P50 that involved the gut microbes.
Still, interesting stuff
Post Edited (DBwithUC) : 5/1/2017 2:13:04 PM (GMT-6)